Uganda Expands Sickle Cell Screening as Early Treatment Offers New Hope

Sickle cell disease remains a significant public health challenge in Uganda, where thousands of babies are born with the inherited blood disorder every year.

The condition can cause severe pain, anaemia and other serious complications. In parts of Africa, delayed diagnosis and limited access to treatment have contributed to poor outcomes for children living with the disease.

Uganda is now expanding newborn screening and early treatment in an effort to identify affected children sooner and prevent complications before they become severe.

A long search for answers

For Irene Nalukwago, the journey to a diagnosis for her daughter lasted years.

Her daughter was born apparently healthy at a hospital in Kayunga, east of Kampala. At around six months, however, she began experiencing repeated illnesses and anaemia.

Nalukwago said her daughter eventually required frequent blood transfusions and experienced severe pain before doctors identified the underlying condition.

Testing later confirmed that she had sickle cell disease.

Now 12, the girl has experienced serious complications associated with the disorder. Nalukwago recalled one episode in which her daughter developed paralysis affecting one side of her body.

Her experience reflects the difficulties faced by families when sickle cell disease is not identified and managed early.

Uganda expands newborn screening

Ugandan health authorities have been increasing efforts to identify sickle cell disease at an early stage through newborn screening.

Early diagnosis allows healthcare providers and families to begin monitoring children before serious complications develop.

At Kayunga Referral Hospital, medical teams are using hydroxyurea as part of routine management for children diagnosed with the condition.

Dr Isaac Tumusiime, a medical officer at the hospital, said children are being started on hydroxyurea at an early age and that maintaining a reliable supply of the medicine has helped improve adherence.

Hydroxyurea is used to reduce complications associated with sickle cell disease, including painful episodes and the need for blood transfusions in many patients.

Early treatment can make a difference

Healthcare professionals emphasise that early diagnosis is an important part of managing sickle cell disease.

Regular medical reviews allow doctors to monitor patients and identify potential complications before they become more serious.

For families, routine follow-up can also provide guidance on medication, nutrition, infection prevention and other aspects of long-term care.

Patients receiving treatment at the Kayunga clinic are encouraged to maintain regular appointments because complications such as stroke can occur in people with sickle cell disease.

Early monitoring can help healthcare teams identify patients who require additional intervention and support.

The promise of gene therapy

While existing treatments can help manage sickle cell disease, scientific advances have raised the possibility of treating the underlying genetic cause.

Gene therapies for sickle cell disease have been approved in some countries, including treatments based on modifying a patient's blood-forming stem cells.

These therapies are designed to address the biological mechanism responsible for the disease rather than simply managing individual symptoms.

However, their availability remains limited, particularly in countries where healthcare systems face substantial financial and infrastructure constraints.

For many African families affected by sickle cell disease, the cost and complexity of advanced gene therapies remain major barriers.

Hope for Ugandan families

At Kayunga Referral Hospital, doctors are therefore focusing on treatments that are currently available while looking toward future developments.

Tumusiime said families are encouraged to continue managing their children's condition with available medicines while maintaining hope that newer treatments, including gene therapy, could eventually become affordable and accessible.

The prospect of a treatment capable of substantially changing the course of sickle cell disease offers hope to families who have spent years managing recurrent pain, hospital visits and other complications.

However, health experts say improving access to diagnosis and proven treatment remains essential.

Prevention through early detection

Uganda's expanded screening programme could help address one of the most important challenges facing children with sickle cell disease: discovering the condition before serious complications develop.

For families such as Nalukwago's, an earlier diagnosis could mean access to appropriate treatment and monitoring much sooner.

As Uganda strengthens its sickle cell response, the combination of newborn screening, consistent access to medicines and regular medical monitoring could help improve outcomes for affected children.

Meanwhile, advances in gene therapy are opening a new chapter in the treatment of the inherited disorder.

For now, however, the priority remains ensuring that children can access diagnosis and effective care early enough to give them the best possible chance of living longer and healthier lives.